Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-09-20
2005-09-20
Saucier, Sandra E. (Department: 1651)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S815000
Reexamination Certificate
active
06946457
ABSTRACT:
This invention provides a method of treating a subject afflicted with sickle cell disease which comprises administering to the subject an amount of an antiviral agent effective to inhibit sickling of a cell in the subject, so as to thereby treat the subject afflicted with sickle cell disease. This invention also provides a method of inhibiting polymerization of hemoglobin which comprises contacting the hemoglobin with an amount of an antiviral agent effective to inhibit polymerization of the hemoglobin, so as to thereby inhibit polymerization of the hemoglobin. This invention further provides a method of inhibiting sickling of a cell which comprises contacting the cell with an amount of an antiviral agent effective to inhibit polymerization of hemoglobin in the cell, so as to thereby inhibit sickling of the cell.
REFERENCES:
patent: 5939456 (1999-08-01), Perrine
Lori et al., “Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replicaton”, Science 266 (5186) : 801-5 (1994).
Lawson et al., “Acute Renal Insufficiency Due to Oral Acyclovir in a Man With Sickle Cell Trait”, Southern Medical Journal 92 (11) : 10943-4 (1999).
Chinowsky, “Thrombotic Thrombocytopenic Purpura Associated With Sickle Cell-Hemoglobin C Disease”, Southern Medical Journal 87 (11) : 1168-71 (1994).
De Castro, “Prevalence of Hepatitis C in Adults with Sickle Cell Disease”, Blood 96 (11) : 15b (2000).
Adachi, K. et al., (1980) “Nucleation-Controlled Aggregation Of Deoxyhemoglobin S Participation Of Hemoglobin A In The Aggregation Of Deoxyhemoglobin S In Concentrated Phosphate Buffer”J. Biol. Chem.255: 3092-3099 (Exhibit 1).
Ballas, S.K. et al., (1989) “Effect Of Hydroxyurea On The Rheological Properties Of Sickle Erythrocytes In Vivo”Am. J. Hematol.32: 104-111 (Exhibit 2).
Bunn, H.F. (1997) “Pathogenesis And Treatment Of Sickle Cell Disease”N. Engl. J. Med.337: 762-769 (Exhibit 3).
Charache, S. et al., (1987) “Hydroxyurea-Induced Augmentation Of Fetal Hemoglobin Production In Patients With Sickle Cell Anemia”Blood69: 109-116 (Exhibit 4).
Charache, S. et al., (1995) “Effect Of Hydroxyurea On The Frequency Of Painful Crises In Sickle Cell Anemia”N. Engl. J. Med.332: 1317-1322 (Exhibit 5).
Charache, S., and C.L. Conley (1964) “Rate Of Sickling Of Red Cells During Deoxygenation Of Blood From Persons With Various Sickling Disorders”Blood24: 25-48 (Exhibit 6).
Dover, G.J. et al., (1986) “Hydroxyurea Induction Of Hemoglobin F Production In Sickle Cell Disease; Relationship Between Cytotoxicity And F Cell Production”Blood67: 735-738 (Exhibit 7).
Ferster, A. et al., (1996) “Hydroxyurea For Treatment Of Severe Sickle Cell Anemia: A Pediatric Clinical Trial”Blood88: 1960-1964 (Exhibit 8).
Gillette, P.N. et al., (1974) “Sodium Cyanate As A Potential Treatment For Sickle Cell Disease”N. Eng. J. Med.290: 654-660 (Exhibit 9).
Goldberg, M.A. et al., (1990) “Treatment Of Sickle Cell Anemia With Hydroxyurea And Erythropoietin”N. Engl. J. Med.323: 366-372 (Exhibit 10).
Hahn, E.V., and E.B. Gillespie (1927) “Sickle Cell Anemia: Report Of A Case Greatly Improved By Splenectomy: Experimental Studies Of Sickle Cell Formation”Arch. Intern. Med.39: 233-254 (Exhibit 11).
Huisman, T.H.J. and A.M. Dozy (1965) “Studies On The Heterogeneity Of Hemoglobin. IX. The Use Of Tris (Hydroxymethyl) Aminomethane-HCI Buffers In The Anion-Exchange Of Chromatography Hemoglobins”J. Chromatog.19: 160-169 (Exhibit 12).
Orringer, E.P. et al., (1991) “Effects Of Hydroxyurea On Hemoglobin F And Water Content In The Red Blood Cells Of Dogs And Of Patients With Sickle Cell Anemia”Blood78: 212-216 (Exhibit 13).
Pauling, L. et al., (1949) “Sickle Cell Anemia, A Molecular Disease”Science110: 543-548 (Exhibit 14).
Steinberg, M.H. (1999) “Management Of Sickle Cell Disease”N. Engl. J. Med.340: 1021-1030 (Exhibit 15).
Rogers, G.P. et al., (1990) “Hemotologic Responses Of Patients With Sickle Cell Disease To Treatment With Hydroxyurea”N. Engl. J. Med.322: 1037-1045 (Exhibit 16).
DeBellis Robert H.
Erlanger Bernard F.
Cooper & Dunham LLP
Saucier Sandra E.
The Trustees of Columbia University in the City of New York
White, Esq. John P.
LandOfFree
Methods of treating sickle cell disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating sickle cell disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating sickle cell disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3439065